Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18947782 | 0.85 | MTNR1A (0.31) | — | |
| SCHEMBL23071802 | 0.82 | BRD4 (0.31) | — | |
| SCHEMBL43231 | 0.79 | HPGD (0.36) | — | |
| SCHEMBL208987 | 0.79 | PRKCA (0.35) | — | |
| SCHEMBL26263126 | 0.76 | TBXAS1 (0.30) | — | |
| SCHEMBL24388720 | 0.76 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL29293697 | 0.75 | PRKCA (0.38) | — | |
| SCHEMBL20091594 | 0.75 | HPGD (0.33) | — | |
| SCHEMBL10068094 | 0.74 | CHRM2 (0.33) | — | |
| SCHEMBL208988 | 0.74 | TSHR (0.36) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563509-B2 | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates | IMMUNOGEN INC. (US) | 2013-10-22 | — | — | US | disclosed |
| EP-1689846-B1 | Conjugates of maytansinoid DM1 with antibody trastuzumab, linked through a non-cleavable linker, and its use in the treatment of tumours | IMMUNOGEN INC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8163888-B2 | Potent, durable cytotoxic agents; tissue targeted therapy; tumors, autoimmune diseases, graft versus host disease, viral and parasite infections | IMMUNOGEN, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110281856-A1 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES | IMMUNOGEN INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7989598-B2 | Antibodies; tissue-targeted therapy; for treatment of tumors, autoimmune diseases, graft rejections, graft versus host disease, viral infections, parasite infections | IMMUNOGEN INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080171856-A1 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES | IMMUNOGEN, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080145374-A1 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES | IMMUNOGEN, INC. (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281856-A1 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES | FOLH1, DNPEP, SELPLG | LMNA 1699/4885 |
| US-20080171856-A1 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES | FOLH1, DNPEP, SELPLG | LMNA 1699/4885 |
| US-20080145374-A1 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES | FOLH1, DNPEP, SELPLG | LMNA 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.